Literature DB >> 11359749

Long term outcome and cost-effectiveness of stenting versus balloon angioplasty for acute myocardial infarction.

H Suryapranata1, J P Ottervanger, E Nibbering, A W van 't Hof, J C Hoorntje, M J de Boer, M J Al, F Zijlstra.   

Abstract

OBJECTIVE: To investigate the long term clinical outcome and cost-effectiveness of stenting compared with balloon angioplasty in patients with acute myocardial infarction.
METHODS: Patients with acute myocardial infarction were randomly allocated to primary stenting (112) or balloon angioplasty (115). The primary end point was the cumulative first event rate of death, non-fatal reinfarction, or target vessel revascularisation. Secondary end points were restenosis at six months and the cost-effectiveness at follow up.
RESULTS: After 24 months, the combined clinical end point of death/reinfarction was 4% after stenting and 11% after balloon angioplasty (p = 0.04). Subsequent target vessel revascularisation was necessary in 15 patients (13%) after stenting and in 39 (34%) after balloon angioplasty (p < 0.001). The cumulative cardiac event-free survival rate was also higher after stenting (84% v 62%, p < 0.001). The angiographic restenosis rate after stenting was less than after balloon angioplasty (12% v 34%, p < 0.001). Despite the higher initial costs of stenting (Dfl 21 484 v Dfl 18 625, p < 0.001), the cumulative costs at 24 months were comparable with those of balloon angioplasty (Dfl 31 423 v Dfl 32 933, p = 0.83).
CONCLUSIONS: Compared with balloon angioplasty, primary stenting for acute myocardial infarction results in a better long term clinical outcome without increased cost.

Entities:  

Mesh:

Year:  2001        PMID: 11359749      PMCID: PMC1729781          DOI: 10.1136/heart.85.6.667

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  23 in total

1.  The volume of primary angioplasty procedures and survival after acute myocardial infarction. National Registry of Myocardial Infarction 2 Investigators.

Authors:  J G Canto; N R Every; D J Magid; W J Rogers; J A Malmgren; P D Frederick; W J French; A J Tiefenbrunn; V K Misra; C I Kiefe; H V Barron
Journal:  N Engl J Med       Date:  2000-05-25       Impact factor: 91.245

2.  Long-term benefit of primary angioplasty as compared with thrombolytic therapy for acute myocardial infarction.

Authors:  F Zijlstra; J C Hoorntje; M J de Boer; S Reiffers; K Miedema; J P Ottervanger; A W van 't Hof; H Suryapranata
Journal:  N Engl J Med       Date:  1999-11-04       Impact factor: 91.245

3.  A cost-effective analysis of primary coronary angioplasty versus thrombolysis for acute myocardial infarction.

Authors:  M J de Boer; B A van Hout; A L Liem; H Suryapranata; J C Hoorntje; F Zijlstra
Journal:  Am J Cardiol       Date:  1995-10-15       Impact factor: 2.778

4.  Effect of glycoprotein IIb/IIIa inhibition without thrombolytic therapy on reperfusion in acute myocardial infarction: results of ReoMI pilot study.

Authors:  R Makkar; B Goff; N Eigler; M Sebastian; T Fischell; L Barr; C D'Haem; P K Shah; M B Effron; F Litvack
Journal:  Catheter Cardiovasc Interv       Date:  1999-12       Impact factor: 2.692

5.  Economic outcomes analysis of stenting versus percutaneous transluminal coronary angioplasty for patients with coronary artery disease in Japan.

Authors:  S Ikeda; J Bosch; K Banz; P Schneller
Journal:  J Invasive Cardiol       Date:  2000-04       Impact factor: 2.022

6.  A comparison of systematic stenting and conventional balloon angioplasty during primary percutaneous transluminal coronary angioplasty for acute myocardial infarction. STENTIM-2 Investigators.

Authors:  L Maillard; M Hamon; K Khalife; P G Steg; F Beygui; J L Guermonprez; C M Spaulding; J M Boulenc; J Lipiecki; A Lafont; P Brunel; G Grollier; R Koning; P Coste; X Favereau; B Lancelin; E Van Belle; P Serruys; J P Monassier; P Raynaud
Journal:  J Am Coll Cardiol       Date:  2000-06       Impact factor: 24.094

7.  Coronary angioplasty with or without stent implantation for acute myocardial infarction. Stent Primary Angioplasty in Myocardial Infarction Study Group.

Authors:  C L Grines; D A Cox; G W Stone; E Garcia; L A Mattos; A Giambartolomei; B R Brodie; O Madonna; M Eijgelshoven; A J Lansky; W W O'Neill; M C Morice
Journal:  N Engl J Med       Date:  1999-12-23       Impact factor: 91.245

8.  A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group.

Authors:  P W Serruys; P de Jaegere; F Kiemeneij; C Macaya; W Rutsch; G Heyndrickx; H Emanuelsson; J Marco; V Legrand; P Materne
Journal:  N Engl J Med       Date:  1994-08-25       Impact factor: 91.245

9.  In-hospital and one-year economic outcomes after coronary stenting or balloon angioplasty. Results from a randomized clinical trial. Stent Restenosis Study Investigators.

Authors:  D J Cohen; H M Krumholz; C A Sukin; K K Ho; R B Siegrist; M Cleman; R R Heuser; J A Brinker; J W Moses; M P Savage
Journal:  Circulation       Date:  1995-11-01       Impact factor: 29.690

10.  Evaluating the potential cost-effectiveness of stenting as a treatment for symptomatic single-vessel coronary disease. Use of a decision-analytic model.

Authors:  D J Cohen; J A Breall; K K Ho; R E Kuntz; L Goldman; D S Baim; M C Weinstein
Journal:  Circulation       Date:  1994-04       Impact factor: 29.690

View more
  9 in total

1.  Can the published cost analysis data for delivery of an efficient primary angioplasty service be applied to the modern National Health Service?

Authors:  N Melikian; K Morgan; K J Beatt
Journal:  Heart       Date:  2005-10       Impact factor: 5.994

2.  Is routine stenting for acute myocardial infarction superior to balloon angioplasty? A randomised comparison in a large cohort of unselected patients.

Authors:  H Suryapranata; G De Luca; A W J van 't Hof; J P Ottervanger; J C A Hoorntje; J-H E Dambrink; A T M Gosselink; F Zijlstra; M-J de Boer
Journal:  Heart       Date:  2005-05       Impact factor: 5.994

3.  Angiographic determinants of infarct size after successful percutaneous intervention for acute ST-elevation myocardial infarction: the impact of distal embolisation.

Authors:  J P S Henriques; F Zijlstra; J P Ottervanger; J-H E Dambrink; A W J van 't Hof; J C A Hoorntje; M-J de Boer; H Suryapranata
Journal:  Neth Heart J       Date:  2002-09       Impact factor: 2.380

4.  Primary Angioplasty for the Treatment of Acute ST-Segment Elevated Myocardial Infarction: An Evidence-Based Analysis.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2004-08-01

5.  Recommendations on percutaneous coronary intervention for the reperfusion of acute ST elevation myocardial infarction.

Authors:  G Montalescot; H R Andersen; D Antoniucci; A Betriu; M J de Boer; L Grip; F J Neumann; M T Rothman
Journal:  Heart       Date:  2004-06       Impact factor: 5.994

Review 6.  A quantitative estimate of bare-metal stenting compared with balloon angioplasty in patients with acute myocardial infarction: angiographic measures in relation to clinical outcome.

Authors:  Tone Svilaas; Iwan C C van der Horst; Felix Zijlstra
Journal:  Heart       Date:  2007-07       Impact factor: 5.994

7.  Short term cost effectiveness of a regional myocardial infarction network.

Authors:  Ralf Birkemeyer; Anke Dauch; Alfred Müller; Manfred Beck; Henrik Schneider; Hueseyin Ince; Werner Jung; Steffen Wahler
Journal:  Health Econ Rev       Date:  2013-04-08

8.  The decline effect in cardiovascular medicine: is the effect of cardiovascular medicine and stent on cardiovascular events decline over the years?

Authors:  Moo-Sik Lee; Andreas J Flammer; Amir Lerman
Journal:  Korean Circ J       Date:  2013-07       Impact factor: 3.243

9.  Up to 15-Year Survival of Men and Women after Percutaneous Coronary Intervention Paid by the Brazilian Public Healthcare System in the State of Rio de Janeiro, 1999-2010.

Authors:  Christina Grüne de Souza E Silva; Carlos Henrique Klein; Paulo Henrique Godoy; Lucia Helena Alvares Salis; Nelson Albuquerque de Souza E Silva
Journal:  Arq Bras Cardiol       Date:  2018-10-18       Impact factor: 2.000

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.